Drug Profile
Interferon alpha biobetter - Vitapharm Technology Development
Latest Information Update: 06 Sep 2017
Price :
$50
*
At a glance
- Originator Vitapharm Technology Development
- Class Antivirals; Biobetters; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C; Neutropenia
Most Recent Events
- 06 Sep 2017 Discontinued - Preclinical for Hepatitis B in China (Sublingual)
- 06 Sep 2017 Discontinued - Preclinical for Hepatitis C in China (Sublingual)
- 06 Sep 2017 Discontinued - Preclinical for Neutropenia (Prevention, Chemotherapy-induced) in China (Sublingual)